Putting your money where your mouth is, Royalty Pharma partners with J&J on $500M drug development deal

Royalty Pharma plc (RPRX) announced a research and development co-funding agreement with Johnson & Johnson for $500 million over 2026 and 2027 to advance development of JNJ-4804, an investigational medicine for autoimmune diseases.

JNJ-4804 is described as a novel co-antibody therapy that blocks both interleukin-23 and tumor necrosis factor pathways, targeting chronic immune-mediated diseases. The drug aims to deliver synergistic effects on the pathogenesis of these conditions.

“We are delighted to collaborate with Johnson & Johnson on the clinical development of JNJ-4804,” said Pablo Legorreta, Chief Executive Officer and Chairman of Royalty Pharma. “Royalty Pharma has a strong track record of investing in immunology, beginning with early disease-modifying biologics including TNF inhibitors.”

Legorreta noted that Johnson & Johnson is a recognized leader in immunology and expressed belief that JNJ-4804 holds substantial promise for patients with chronic immune-mediated diseases. He characterized the collaboration as building on the company’s commitment to partnering with global biopharmaceutical companies.

Founded in 1996, Royalty Pharma positions itself as the largest buyer of biopharmaceutical royalties. The company’s portfolio includes royalties on more than 35 commercial products and 19 development-stage product candidates, according to the press release.